Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dutch start-up uniQure nets $85.4mm in US IPO

Executive Summary

Gene therapy start-up uniQure BV netted $85.4mm in its US initial public offering. The company sold 5.4mm ordinary shares (more than the 4.6mm planned) for $17, above its $13-15 price range. Existing investors Forbion, Gilde, and Coller agreed to buy 1.2mm of the IPO shares.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies